US 12,281,142 B2
Recombinant HIV Env polypeptides and their use
Jon M. Steichen, La Jolla, CA (US); and William R. Schief, La Jolla, CA (US)
Assigned to International AIDS Vaccine Initiative, Inc., New York, NY (US); and The Scripps Research Institute, La Jolla, CA (US)
Filed by International AIDS Vaccine Initiative, Inc., New York, NY (US); and The Scripps Research Institute, La Jolla, CA (US)
Filed on Jun. 1, 2021, as Appl. No. 17/335,244.
Application 17/335,244 is a continuation in part of application No. PCT/US2019/063903, filed on Dec. 1, 2019.
Claims priority of provisional application 62/774,178, filed on Dec. 1, 2018.
Prior Publication US 2021/0363195 A1, Nov. 25, 2021
Int. Cl. C07K 14/16 (2006.01); A61K 9/51 (2006.01); A61K 38/00 (2006.01); A61K 39/21 (2006.01); C07K 16/10 (2006.01); C12N 7/00 (2006.01)
CPC C07K 14/162 (2013.01) [A61K 9/5169 (2013.01); A61K 39/21 (2013.01); C07K 16/1063 (2013.01); C12N 7/00 (2013.01); A61K 38/00 (2013.01); C07K 2317/565 (2013.01); C12N 2740/16134 (2013.01)] 16 Claims
 
1. An isolated polypeptide comprising a variant HIV Env gp120 polypeptide,
wherein the variant HIV Env gp120 polypeptide comprises
a V1 loop comprising positions 131-154,
a V3 loop comprising positions 297-334, and
a β19 sheet comprising positions 413-419, and
wherein the V1 loop, positions 297-303 of the V3 loop, positions 319-334 of the V3 loop,
and the β19 sheet comprise:
 
 (q)
 
 (SEQ ID NO: 74)
 
 CTNYAPKLLSNMRGEI, 
 
 (SEQ ID NO: 77)
 
 TRPNNNT,
 
 (SEQ ID NO: 82)
 
 FGDVLGHVRMAHCNIS, and 
 
 (SEQ ID NO: 86)
 
 SLILPCR,
 
 respectively,
 
 
 
 (r)
 
 (SEQ ID NO: 75)
 
 CTNYAPKLRSMMRGEI, 
 
 (SEQ ID NO: 77)
 
 TRPNNNT,
 
 (SEQ ID NO: 81)
 
 FGDVLGDVRMAHCNIS, and 
 
 (SEQ ID NO: 86)
 
 SLILPCR,
 
 respectively,
 
 
 
 (s)
 
 (SEQ ID NO: 75)
 
 CTNYAPKLRSMMRGEI, 
 
 (SEQ ID NO: 77)
 
 TRPNNNT,
 
 (SEQ ID NO: 82)
 
 FGDVLGHVRMAHCNIS, and 
 
 (SEQ ID NO: 86)
 
 SLILPCR,
 
 respectively,
 
 
 
 (t)
 
 (SEQ ID NO: 75)
 
 CTNYAPKLRSMMRGEI, 
 
 (SEQ ID NO: 78)
 
 TRPSNNT,
 
 (SEQ ID NO: 82)
 
 FGDVLGHVRMAHCNIS, and 
 
 (SEQ ID NO: 86)
 
 SLILPCR,
 
 respectively,
 
 
 
 (u)
 
 (SEQ ID NO: 75)
 
 CTNYAPKLRSMMRGEI, 
 
 (SEQ ID NO: 78)
 
 TRPSNNT,
 
 (SEQ ID NO: 82)
 
 FGDVLGHVRMAHCNIS, and 
 
 (SEQ ID NO: 87)
 
 SLILPCW,
 
 respectively,
 
 
 
 (v) 
 
 (SEQ ID NO: 76)
 
 CTNYAPNLRSDMRGEI, 
 
 (SEQ ID NO: 77)
 
 TRPNNNT,
 
 (SEQ ID NO: 83)
 
 FGDVLGDVDMAKCTIS, and 
 
 (SEQ ID NO: 86)
 
 SLILPCR,
 
 respectively,
 
 
 
 (w) 
 
 (SEQ ID NO: 74)
 
 CTNYAPKLLSNMRGEI, 
 
 (SEQ ID NO: 77)
 
 TRPNNNT,
 
 (SEQ ID NO: 79)
 
 TGDIIGDIRQAHCNVS, and 
 
 (SEQ ID NO: 84)
 
 SITLPCR,
 
 respectively,
 
 
 
 (x) 
 
 (SEQ ID NO: 73)
 
 CTNYAPNLLSNMRGEI 
 
 (SEQ ID NO: 77)
 
 TRPNNNT,
 
 (SEQ ID NO: 80)
 
 FGDIIGDIRMAHCNVS, and 
 
 (SEQ ID NO: 85)
 
 SIVLPCR,
 
 respectively,
 
 
 
 (y) 
 
 (SEQ ID NO: 73)
 
 CTNYAPNLLSNMRGEI, 
 
 (SEQ ID NO: 77)
 
 TRPNNNT,
 
 (SEQ ID NO: 81)
 
 FGDVLGDVRMAHCNIS, and 
 
 (SEQ ID NO: 86)
 
 SLILPCR,
 
 respectively, or
 
 
 
 (z) 
 
 (SEQ ID NO: 75)
 
 CTNYAPKLRSMMRGEI, 
 
 (SEQ ID NO: 77)
 
 TRPNNNT,
 
 (SEQ ID NO: 81)
 
 FGDVLGDVRMAHCNIS, and 
 
 (SEQ ID NO: 86)
 
 SLILPCR,
 
 respectively,
and wherein HIV Env gp120 polypeptide positions correspond to the HXB2 reference.